Skip to content

Efficacy and safety of endovascular thrombectomy combined with medical management versus medical management alone for acute large vessel occlusion stroke beyond 24 hours after symptom onset: a multicenter cohort study (DELAY)

Efficacy and safety of endovascular thrombectomy combined with medical management versus medical management alone for acute large vessel occlusion stroke beyond 24 hours after symptom onset: a multicenter cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400086375
Enrollment
Unknown
Registered
2024-07-01
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute stroke

Interventions

medical management group:NA

Sponsors

Sichuan Mianyang 404 Hospital (Mianyang First People's Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed as acute ischemic stroke based on clinical symptoms or imaging examination; (2) The interval from the onset of the disease or the last normal time to the start of treatment is greater than 24 hours; (3) CTA/MRA/DSA clearly indicates occlusion of the internal carotid artery, middle cerebral artery M1 or M2 segment, or vertebrobasilar artery; (4) The patient or family member signs a written informed consent form.

Exclusion criteria

Exclusion criteria: (1) Confirmed intracranial hemorrhage by CT or MRI; (2) Brain herniation and midline deviation; (3) Previous hemorrhagic diseases, severe heart, liver or kidney diseases, or sepsis; Late stage of any disease results in an expected lifespan of less than 6 months.

Design outcomes

Primary

MeasureTime frame
90-day modified Rankin scale score ;

Secondary

MeasureTime frame
90-day modified Rankin scale score of 0-1;90-day modified Rankin scale score of 0-3;NIHSS score at 5-7 days postoperatively;The success rate of perfusion at the end of intravascular treatment (defined as eTICI score=2b);Incidence of symptomatic intracranial hemorrhage within 48 hours (according to Heidelberg typing criteria);Incidence of any intracranial hemorrhage within 48 hours;Incidence of non-intracranial hemorrhage complications (bleeding from the oral cavity, gastrointestinal tract, urinary tract, etc.);Mortality within 90 days;Operative and device-related complications (including arterial rupture, arterial entrapment, implantation failure, stent fracture, vascular puncture point complications, vasospasm, and device failure);Incidence of non-hemorrhagic serious adverse events (including brain herniation, pneumonia, respiratory failure, circulatory failure, stress ulcers, secondary epilepsy, urinary tract infections, sepsis, renal failure, acute coronary syndromes, venous thrombosis, and psychiatric symptoms);

Countries

China

Contacts

Public ContactJun Luo

Sichuan Mianyang 404 Hospital (Mianyang First People's Hospital)

luojunlenovo@163.com+86 135 1831 9060

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026